UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.